View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Market Data
November 13, 2011

Anacor completes patient enrollment for AN2690 drug study

Anacor Pharmaceuticals has concluded patient enrollment in the first of two Phase 3 trials of a topical anti-fungal product Tavaborole (AN2690), used to treat onychomycosis.

Anacor Pharmaceuticals has concluded patient enrollment in the first of two Phase 3 trials of a topical anti-fungal product Tavaborole (AN2690), used to treat onychomycosis.

The Phase 3 trial includes two double-blind vehicle-controlled trials with two-to-one randomisation between tavaborole and vehicle (the topical formulation without the active ingredient).

As per Special Protocol Assessment with the FDA, the primary efficacy endpoint is a complete cure of the great toenail at week 52.

Anacor Pharmaceuticals CEO David Perry said they hope tavaborole can provide improved standards of care for onychomycosis.

"We have completed enrollment of approximately 600 patients in the first of two Phase 3 trials for Tavaborole. We expect to complete enrollment in our second Phase 3 trial by year-end 2011," Perry added.

The study results are expected by the end of 2012.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena